Abstract
Suppression of cell death (most often apoptosis) by survival signals, or by defects in cell death signal transduction pathways, is considered one of the obligate hallmarks of malignant transformation. However, molecular survival strategies to evade cell death only have relevance in the presence of pro-death signals. Discovery of the apoptotic properties of oncogenes responsible for increased tumor cell proliferation (e.g. c-Myc) provided the most important example for such signals and led to the concept of synthetic lethal targeting as a strategy of identifying cancer specific drug target molecules. Besides growth signal autonomy, other hallmarks of oncogenesis (insensitivity to anti-growth signals, limitless replicative potential, invasion and metastasis, angiogenesis and increased genomic instability) are also challenged by increased susceptibility to various forms of cell death. Therefore, cancer cells must acquire survival strategies to suppress these cell death/apoptosis mechanisms. Novel signal transduction therapies can target molecules involved in these strategies to trigger tumor specific cell death.
Keywords: Cell death, apoptosis, cancer
Current Signal Transduction Therapy
Title: Molecular Targeting of Cell Death Signal Transduction Pathways in Cancer
Volume: 1 Issue: 1
Author(s): Istvan Petak, Janet A. Houghton and Laszlo Kopper
Affiliation:
Keywords: Cell death, apoptosis, cancer
Abstract: Suppression of cell death (most often apoptosis) by survival signals, or by defects in cell death signal transduction pathways, is considered one of the obligate hallmarks of malignant transformation. However, molecular survival strategies to evade cell death only have relevance in the presence of pro-death signals. Discovery of the apoptotic properties of oncogenes responsible for increased tumor cell proliferation (e.g. c-Myc) provided the most important example for such signals and led to the concept of synthetic lethal targeting as a strategy of identifying cancer specific drug target molecules. Besides growth signal autonomy, other hallmarks of oncogenesis (insensitivity to anti-growth signals, limitless replicative potential, invasion and metastasis, angiogenesis and increased genomic instability) are also challenged by increased susceptibility to various forms of cell death. Therefore, cancer cells must acquire survival strategies to suppress these cell death/apoptosis mechanisms. Novel signal transduction therapies can target molecules involved in these strategies to trigger tumor specific cell death.
Export Options
About this article
Cite this article as:
Petak Istvan, Houghton A. Janet and Kopper Laszlo, Molecular Targeting of Cell Death Signal Transduction Pathways in Cancer, Current Signal Transduction Therapy 2006; 1 (1) . https://dx.doi.org/10.2174/157436206775269217
DOI https://dx.doi.org/10.2174/157436206775269217 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oncolytic Virotherapy for Breast Cancer Treatment
Current Gene Therapy Differentiation Potential of Human Retinoblastoma Cells
Current Pharmaceutical Biotechnology DNA Methylation as a Target of Epigenetic Therapeutics in Cancer
Anti-Cancer Agents in Medicinal Chemistry The ErbB Receptors and their Ligands in Cancer: An Overview
Current Drug Targets miRNAs in Cancer Prevention and Treatment and as Molecular Targets for Natural Product Anticancer Agents
Current Cancer Drug Targets ABC Transporters as Potential Targets for Modulation of Drug Resistance
Mini-Reviews in Medicinal Chemistry Oligonucleotide Aptamers for Glioma Targeting: An Update
Central Nervous System Agents in Medicinal Chemistry In Vivo Apoptosis Imaging Agents and Strategies
Anti-Cancer Agents in Medicinal Chemistry Impact of Drug Metabolism/Pharmacokinetics and their Relevance Upon Taxus-based Drug Development
Current Drug Metabolism The Anti-Cancer Activity of Noscapine: A Review
Recent Patents on Anti-Cancer Drug Discovery Exploiting Metabolic Differences in Glioma Therapy
Current Drug Discovery Technologies Drug Delivery Systems for Brain Tumor Therapy
Current Pharmaceutical Design CD44 and EpCAM: Cancer-Initiating Cell Markers
Current Molecular Medicine Role of Isoprenoid Compounds on Angiogenic Regulation: Opportunities and Challenges
Current Medicinal Chemistry Liposome-Nanogel Structures for Future Pharmaceutical Applications
Current Pharmaceutical Design Novel Agents Targeting Bioactive Sphingolipids for the Treatment of Cancer
Current Medicinal Chemistry A Prooxidant Mechanism for the Anticancer and Chemopreventive Properties of Plant Polyphenols
Current Drug Targets Fluoride Interactions: From Molecules to Disease
Current Signal Transduction Therapy Nanobiotechnology-based Drug Delivery in Brain Targeting
Current Pharmaceutical Biotechnology Eliminating Ovarian Cancer Stem Cells: A Potential Therapeutic Target for Ovarian Cancer Chemoresistance
Current Protein & Peptide Science